The current study aimed to assess whether T2DM in midlife, the time-period when T2DM is acting as a risk factor for cognitive dysfunction, was associated with altered PBMC immune responses to various NLRP3 agonists including Aβ-42, the putative pathogenic protein in AD. The gene discussed is NLRP3; the disease is Alzheimer disease.